Loading...
•
Dec 31, 2022
Bristol-Myers Squibb Q4 2022 Earnings Report
Reported fourth quarter revenues of $11.4 billion and full-year revenues of $46.2 billion.
Key Takeaways
Bristol Myers Squibb reported a decrease in fourth-quarter revenues by 5% to $11.4 billion, driven by recent LOE products and foreign exchange impacts, which was partially offset by in-line products and new product portfolio. The company reported GAAP EPS of $0.95 and non-GAAP EPS of $1.82 for the quarter.
Fourth Quarter Revenues from In-Line Products and New Product Portfolio were $9.0 Billion, an Increase of 7%, or 12% When Adjusted for Foreign Exchange
Fourth Quarter GAAP EPS was $0.95 and Non-GAAP EPS was $1.82, including Net Impact of ($0.01) Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income
Full-Year GAAP EPS was $2.95 and Non-GAAP EPS was $7.70, including Net Impact of ($0.24) Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income
Provided GAAP and Non-GAAP Financial Guidance for 2023 Reflecting Continued Revenue and Earnings Growth
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb Revenue by Segment
Revenue by Segment
Net Product Sales Revenue
CapyFin.comAlliance and Other Revenues Revenue
CapyFin.com Forward Guidance
Bristol Myers Squibb provides its 2023 GAAP EPS guidance range of $4.03 - $4.33 and its non-GAAP EPS guidance range of $7.95 - $8.25.
Positive Outlook
- Total revenues are expected to increase by approximately 2% at reported rates and approximately 2% excluding foreign exchange.
- Revenues from Revlimid are expected to be approximately $6.5 billion.
- Gross margin is expected to be approximately 77% for GAAP and for non-GAAP.
- Operating expenses are expected to decrease by mid-single digits for GAAP and decrease by low single digits for non-GAAP.
- An effective tax rate of approximately 22% for GAAP and approximately 17% for non-GAAP.
Revenue & Expenses
Visualization of income flow from segment revenue to net income